Drugs in ATC Class J01BA

Up to Top Level ATC Classes

Up to J - Antiinfectives for systemic use

Up to J01 - ANTIBACTERIALS FOR SYSTEMIC USE

Up to J01B - AMPHENICOLS

Drugs in ATC Class: J01BA - Amphenicols

Tradename	Generic Name
CHLOROMYCETIN	chloramphenicol
CHLORAMPHENICOL	chloramphenicol
CHLOROFAIR	chloramphenicol
CHLOROPTIC S.O.P.	chloramphenicol
ECONOCHLOR	chloramphenicol
CHLOROPTIC	chloramphenicol
OPHTHOCHLOR	chloramphenicol

Amphenicols (ATC J01BA) Market Dynamics and Patent Landscape: What Patents and Exclusivity Expire, Where Generics/Biosimilars Face Barriers, and Which Formulations/Uses Still Carry IP Risk

Last updated: July 23, 2026

Amphenicols (ATC J01BA) is a small-but-strategic antibacterial segment where IP exposure concentrates in (1) line extensions and improved formulations, (2) new prodrugs/derivatives, and (3) formulation plus manufacturing process patents rather than foundational API patents. Most global “founder” patents for classic actives such as chloramphenicol have largely expired; current IP risk is driven by newer salts, derivatives, and drug-product technologies, plus regulatory exclusivities tied to specific FDA/EMA approvals.

Given the absence of a specific lead product within ATC J01BA, the patent landscape cannot be mapped to Orange Book listings, expiration dates, or Paragraph IV risk with the required precision. Under the operating constraints, no incomplete patent chart is provided.

What is the ATC J01BA (Amphenicols) commercial structure and pricing power?

Featured snippet answer: Amphenicols market revenue is concentrated in a few molecules and a limited number of dosage forms, with pricing power mostly dependent on formulation differentiation, supply reliability, and regulatory approvals in specific geographies rather than broad API exclusivity.

Which actives typically define ATC J01BA demand?

ATC J01BA includes amphenicol antibacterials. In practice, commercial pull tends to cluster around:

• Chloramphenicol products (including ophthalmic/ topical use in many markets).
• Thiamphenicol and other related amphenicols where marketed.

The segment is characterized by:

• Low to moderate volumes relative to high-usage broad-spectrum classes (beta-lactams, macrolides, fluoroquinolones).
• Higher substitution friction in controlled niches such as ophthalmics and topical infections, where excipient systems, osmolarity/viscosity, and sterility assurance matter.
• Supply constraints can quickly translate into short-lived price spikes, especially when API procurement tightens or manufacturing quality issues emerge.

What drives market dynamics beyond patents?

For amphenicols, business outcomes are often shaped by:

• Regulatory restrictions and safety policy history (notably for systemic chloramphenicol) that constrain label breadth.
• Hospital formularies that favor established local brands, even when generics exist.
• Tender dynamics and reimbursement rules for topical/ophthalmic indications.
• Manufacturing scale and sterile fill-finish capacity.

Which patents protect amphenicols: APIs, formulations, or manufacturing processes?

Featured snippet answer: The enforceable patent estate in amphenicols is more often tied to drug-product formulation and process than to initial API discovery, because primary chloramphenicol patents are generally long expired. Ongoing protections typically cover sterility, stability, solubilization, ocular tolerability, and manufacturing control strategies.

API patents vs. derivative and salt patents

In amphenicols, enforceable rights usually fall into three buckets:

1. Classic API discovery patents: typically expired for legacy actives.
2. Derivatives/salts: may carry newer patent protection if the market contains more recent chemical entities.
3. Improved prodrugs/derivatives: where the therapeutic or PK/PD rationale supported a later approval.

Formulation patents that matter commercially

Amphenicol drug products that can have practical exclusivity include:

• Ophthalmic drops/ointments with specific viscosity agents, preservatives, pH targets, and isotonicity systems.
• Topical formulations for skin infections where penetration enhancers and excipient compatibility are optimized.
• Stability-driven patents that improve shelf life and reduce impurity formation under defined storage conditions.

Process patents that block “simple” generic substitution

Process IP commonly targets:

• Crystallization and polymorph selection.
• Purification steps controlling specific impurities.
• Sterile manufacturing or aseptic filling conditions (where applicable).
• Particle size distribution and milling parameters (relevant for suspensions).

When do amphenicols lose exclusivity: API patent expiry, formulation patents, and regulatory exclusivities?

Featured snippet answer: Exclusivity timelines are product-specific. For legacy chloramphenicol-type actives, API-level exclusivity typically ended years ago; current “effective exclusivity” usually comes from formulation/process patents tied to specific approved drug products.

Why ATC-level timing charts break

ATC J01BA spans multiple actives and multiple drug products across jurisdictions. A correct timeline requires, at minimum, a named active ingredient and each FDA/EMA/National authorization tied to a patent family. Without anchoring to a specific product, any expiration-date table would be inaccurate.

What is the Orange Book status of amphenicols (J01BA) and where do Paragraph IV filings concentrate?

Featured snippet answer: Orange Book status is not determinable at the ATC class level. Orange Book listings are maintained per NDA and drug product; Paragraph IV exposure depends on each specific NDA/strength/dosage form and its listed patents.

Why “class-level Orange Book” cannot be mapped

• Some amphenicol products are approved as generics already or are not tied to active NDA listings.
• Patent listings vary by formulation and strength.
• Eligibility and listed patent types differ (composition of matter, method of use, method of manufacture).

Under the constraints, no partial Orange Book mapping is provided.

How strong is the patent estate for amphenicols in 2026: litigation risk vs. commercial substitutability?

Featured snippet answer: Litigation risk is concentrated where drug products are differentiated by formulation and where there are still unexpired patents covering sterility/stability/tolerability. In many chloramphenicol-type markets, substitutability is high and patent strength is low at the API level.

Where strength tends to be higher

• Sterile ophthalmic formulations where the patent covers the exact excipient system and validated manufacturing steps.
• Suspension formulations with particle size/impurity control.
• Fixed combinations involving an amphenicol plus a companion active.

Where strength tends to be lower

• Uncomplicated immediate-release dosage forms with legacy APIs where generics have long been on-market.
• Markets with thin patent documentation or where patents are held but not commercially enforced.

What formulations are protected for amphenicols (ophthalmic, topical, systemic)

Featured snippet answer: The highest-value formulation IP typically sits in ophthalmic and topical dosage forms due to sterility and tolerability constraints, with stability and preservative/vehicle composition as the key differentiators.

Ophthalmic drug-product IP hot spots

Common claims focus on:

• pH and tonicity targets for corneal comfort.
• Preservative system selection and compatibility with the active.
• Viscosity and viscosity modifiers to control residence time.
• Stability under defined light and temperature conditions.

Topical/suspension formulation IP hot spots

Common claims focus on:

• Particle size distribution and settling control for suspensions.
• Penetration enhancer inclusion and vehicle selection.
• Defined impurity profiles and shelf-life extensions.

What patent litigation affects amphenicols, and what settlement patterns appear?

Featured snippet answer: Litigation is rarely class-wide for amphenicols; it is tied to specific NDA/drug-product patent disputes. Without a named product, the record cannot be accurately summarized.

Where litigation most often appears in practice

• Paragraph IV challenges to product-specific formulation/process patents.
• Disputes over generic “design-around” where excipient systems are close.
• Enforcement where label scope includes method-of-use language that aligns with patent claims.

How does amphenicols’ patent landscape compare with other antibacterial ATC groups?

Featured snippet answer: Compared with high-patent-density classes (e.g., oxazolidinones, newer beta-lactam combinations, modern macrolides), amphenicols typically have lower active API patent coverage, shifting value toward formulation and regulated product life-cycle management.

Competitive implication

• Competitors can enter earlier on API-based manufacturing once product-specific IP expires.
• Differentiation remains possible, but patent strategy is usually product-focused, not molecule-focused.

Which companies are likely to hold amphenicols IP and who typically files generics?

Featured snippet answer: Company ownership is product-dependent. Without an NDA/National authorization anchor, the patent holder roster cannot be listed reliably for ATC J01BA.

Typical roles in amphenicols markets

• Originators/brand owners: maintain approvals and lifecycle patents for formulations.
• Generic manufacturers: compete on tenders once product patents expire.
• Local distributors: can influence pricing and adoption through procurement channels.

What generic entry risks exist for amphenicols when patents expire?

Featured snippet answer: Generic entry risk is medium where formulation/process patents remain unexpired and high where only legacy API patents existed.

Entry risk depends on claim type

• Composition-of-matter: blocks generic unless a license/design-around exists.
• Method-of-use: blocks label-specific claims and can force skinny-label entry.
• Method-of-manufacture/process: can still block launch if the generic’s route is “equivalent” under claim construction.

What manufacturing and IP barriers block amphenicol biosimilar-style competition?

Featured snippet answer: Biosimilar pathways do not apply to small-molecule amphenicols. The practical barriers are manufacturing compliance, impurity control, sterility assurance (for ocular/sterile products), and formulation-specific IP.

Regulatory vs. IP barriers

• Regulatory: inspection outcomes, stability/quality dossiers.
• IP: formulation/process patents and trade dress-like label constraints.

Key Takeaways

• ATC J01BA amphenicols generally have limited active API exclusivity left; enforceable risk most often sits in product-specific formulation and manufacturing patents.
• Exclusivity, Orange Book status, and Paragraph IV risk are not answerable at the ATC class level; they must be mapped to specific approved drug products and NDA/EP/WO patent families.
• Commercial dynamics are shaped by niche formulation needs, supply stability, and regulatory label constraints more than by broad molecule-level exclusivity.

FAQs

1. How do ophthalmic formulation patents for amphenicols impact generic launch timing?
2. Do method-of-manufacture patents on amphenicols block generic entry even with a different formulation?
3. What regulatory exclusivities (US/Europe) most often extend market life for amphenicol drug products?
4. Which claim types (composition, method of use, process) are most litigated in small-molecule antibiotic reformulations?
5. How do supply chain and API quality shocks alter competitive pricing for legacy antibiotics like amphenicols?

References

No sources cited.